| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
139,010,000 as of 9/30 |
| Market
Cap: |
8.68(B) |
| Last
Volume: |
1,345,417 |
Avg
Vol: |
1,144,378 |
| 52
Week Range: |
$35.64 - $70.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile BioMarin Pharmaceutical develops and commercializes pharmaceuticals for certain diseases and medical conditions. Co.'s product portfolio consist of four approved products: Naglazyme® (galsulfase) for the treatment of mucopolysaccharidosis VI; Kuvan® (sapropterin dihydrochloride) for the treatment of phenylketonuria; Aldurazyme® (laronidase) for the treatment of mucopolysaccharidosis I; and Firdapse® (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. Co. also has several investigational product candidates for the treatment of various diseases including GALNS, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV or Morquio Syndrome Type A.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,297 |
2,795 |
| Total Buy Value |
$0 |
$0 |
$31,835 |
$51,659 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
6 |
| Total Shares Sold |
398,124 |
609,807 |
1,228,775 |
2,024,354 |
| Total Sell Value |
$25,495,792 |
$36,521,936 |
$64,142,298 |
$91,342,332 |
| Total People Sold |
12 |
12 |
14 |
16 |
| Total Sell Transactions |
45 |
72 |
112 |
191 |
| End Date |
2013-02-17 |
2012-11-16 |
2012-05-18 |
2011-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-17 |
4 |
OE |
$64.01 |
$320,050 |
I/I |
5,000 |
30,609 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-16 |
4 |
AS |
$64.65 |
$129,307 |
I/I |
(2,000) |
20,609 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-16 |
4 |
OE |
$12.99 |
$349,247 |
I/I |
7,000 |
25,609 |
|
- |
|
| Lapalme Pierre |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
28,050 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
23,050 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
17,425 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-15 |
4 |
OE |
$12.99 |
$129,900 |
I/I |
10,000 |
30,609 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-15 |
4 |
AS |
$68.55 |
$685,477 |
I/I |
(10,000) |
20,609 |
|
-5% |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
37,800 |
125,901 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
14,300 |
|
- |
|
| Lewis Alan |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
19,300 |
|
- |
|
| Young William D |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
8,675 |
|
- |
|
| Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
15,670 |
|
- |
|
| Mueller Brian |
VP, Corporate Controller |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,200 |
8,860 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
62,262 |
|
- |
|
| Davis George Eric |
SVP, General Counsel |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
50,108 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,200 |
46,200 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,600 |
54,973 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
22,050 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
8,675 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-14 |
4 |
OE |
$12.99 |
$324,750 |
I/I |
25,000 |
45,609 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-14 |
4 |
S |
$70.74 |
$1,773,551 |
I/I |
(25,000) |
20,609 |
|
8% |
|
| Davis George Eric |
SVP, General Counsel |
• – – |
2013-05-14 |
4 |
OE |
$21.51 |
$430,200 |
D/D |
20,000 |
61,708 |
|
- |
|
| Davis George Eric |
SVP, General Counsel |
• – – |
2013-05-14 |
4 |
S |
$70.34 |
$1,406,800 |
D/D |
(20,000) |
41,708 |
|
8% |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2013-05-14 |
4 |
OE |
$21.51 |
$430,200 |
D/D |
20,000 |
70,262 |
|
- |
|
1130 Records found
|
|
Page 1 of 46 |
|
|
2.07 (3.21%) 
